AIDS mortality in China drops by nearly two thirds since 2002 when country began free treatment program

NewsGuard 100/100 Score

China's HIV/AIDS-related mortality has dropped from 39.3 per 100 person-years in 2002 to 14.2 in 2009, or 64 percent, since the nation began providing free antiretroviral therapy (ART) in 2002, according to a study conducted by researchers from the Chinese Center for Disease Control and Prevention and published online Wednesday in Lancet Infectious Diseases, the New York Times reports (McNeil, 5/18). About 63 percent of people living with HIV in China are receiving ART, according to the study, Bloomberg notes. The study also found injecting drug users and those infected sexually are less likely to receive treatment and more likely to die than people infected through blood transfusions, the news service reports (Bennett, 5/18). 

According to the Telegraph, "[t]he study praised the impact of Chinese government efforts to combat the disease and showed 'the difference that can be made with high-level political commitment,'" but also said much more needed to be done to reach the estimated 740,000 people living with HIV in China (Foster, 5/19).


    http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

    Comments

    The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
    Post a new comment
    Post

    While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

    Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

    Please do not ask questions that use sensitive or confidential information.

    Read the full Terms & Conditions.

    You might also like...
    ChatGPT aids in discovering potential Alzheimer’s treatments through drug repurposing